Alpalhão, Miguel https://orcid.org/0000-0001-7672-0395
Duarte, Joana
Diogo, Rita
Vandemeulebroecke, Marc
Ortmann, Christine-Elke
Kasparek, Torben
Filipe, Paulo
Clinical trials referenced in this document:
Documents that mention this clinical trial
Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region
https://doi.org/10.1007/s40259-022-00558-2
Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis
https://doi.org/10.1007/s13555-021-00654-1
Documents that mention this clinical trial
Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region
https://doi.org/10.1007/s40259-022-00558-2
Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis
https://doi.org/10.1007/s13555-021-00654-1
Funding for this research was provided by:
Novartis Pharma AG
Article History
Accepted: 24 September 2022
First Online: 5 November 2022
Declarations
:
: This study was funded by Novartis Pharma AG. The funder had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
: Miguel Alpalhão collaborated with the pharmaceutical industry as a speaker for Almirall, Janssen, Leo and Sanofi, a scientific consultant for AbbVie and Novartis, and has participated as an investigator in multicentric clinical trials with AbbVie, Eli-Lilly, Leo and Novartis. Rita Diogo, Marc Vandemeulebroecke, Christine-Elke Ortmann and Torben Kasparek are employees of Novartis. Joana Duarte was an employee of Novartis during study conduct and until manuscript development. Paulo Filipe has collaborated with the pharmaceutical industry as a speaker, scientific consultant and investigator in multicentric clinical trials with AbbVie, Almirall, Boehringer-Ingelheim, Eli-Lilly, Janssen, Leo, Merck-Sharp-Dohme (MSD), Novartis, Pfizer and Sanofi.
: This study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The protocols were approved by the relevant institutional review board or ethics committee at each study site.
: Written informed consent was obtained from all individual participants included in both studies.
: Not applicable.
: Not applicable.
: The datasets generated and/or analysed during the current study are not publicly available. Novartis is committed to sharing with qualified external researchers access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved based on scientific merit. All data provided are anonymised to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The data may be requested from the corresponding author.
: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by TK, JD, RD, C-EO and MV. All authors contributed to drafting and critical appraisal of the manuscript and approved the final version for submission.
: This study was presented in part at 29th European Academy of Dermatology and Venereology, Virtual Congress, 29–31 October, 2020.